Hydron Biotech to List in Late June, Focusing on High-End Medical Devices and Supply Chain

Central News Agency, Taipei, June 2. Hydron Biotech, a collagen-based medical device manufacturer with nearly 70% ownership by the Gin-Ko Group, is expected to list in late June with a tentative offering price of NT$35. General Manager Ho Hsin-yu stated that the company will deepen its layout in dental and surgical devices, collaborate with Taiwan Sugar and Taiwan Livestock to build a medical-grade raw material supply chain, and advance the development of high-end devices like biodegradable ureteral stents as its dual growth engines. Hydron Biotech held a media event today, with shareholders including Gin-Ko Group, Taiwania Capital, and Compal Electronics. Ho noted that the company focuses on collagen medical devices, with core products covering dental protection materials, matrices, membranes, and bone fillers. These are currently used in major institutions like Chang Gung Memorial Hospital, providing stable cash flow. Beyond existing products, Hydron is developing high-end devices, including a biodegradable ureteral stent that has secured a Taiwanese patent. The company is pursuing international patents to enter the global urology market. Regarding supply chain strategy, Hydron is leveraging Taiwan's 'swine disease-free' status to build a medical-grade animal-derived raw material supply chain with Taiwan Sugar and Taiwan Livestock. This ensures quality and supply, with the potential to become an international supplier for global medical device giants. Future plans include expanding into Southeast Asia, entering the veterinary market, and increasing the proportion of high-margin products to boost profitability.